Risk-Adapted Optimization of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early-Stage Breast Cancer.
Personalized approaches to early breast cancer treatment are becoming more precise, allowing doctors to tailor therapy to each patient's tumor.
This PubMed record reports: Together, these advances support a more precise, individualized approach to caring for patients with early-stage HER2-positive breast cancer. The finding is retained for rapid triage and requires downstream evidence review before clinical interpretation.
What the study was
- Study design
- Randomized controlled trial
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Why it surfaced
Retained because its randomized controlled trial evidence is relevant to Early cancer detection (liquid biopsy, ctDNA, cfDNA); scoring is conservative for the available metadata.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.